DUBLIN - June 24, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world clinical outcomes for 32,178 users of the MiniMed(TM) 670G system. Data on more than 2 ...

Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.

The multi-center study had enrolled 105 participants within the 7-13 years’ age group. The trial had a two-week run-in phase and a study period of three months. Notably, 97% of the participants chose ...

Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...

The FDA has expanded its indication for Medtronic’s Guardian Sensor 3, allowing patients to wear the sensor on their upper arm. The sensor is part of Medtronic’s MiniMed 670G system, and is currently ...

DUBLIN, Sept. 1, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its ...

DUBLIN, June 11, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Marking of its MiniMed™ 780G system, a next ...

The MiniMed 780G system has been approved for children aged 7 years and up with type 1 diabetes (T1D), according to Medtronic. The FDA has approved Medtronic’s MiniMed 780G system with Guardian 4 ...

Medtronic's next-generation automated insulin delivery system, the MiniMed 780G, has received a CE mark for the treatment of type 1 diabetes in people aged 7 to 80 years, which means it can be ...

The MiniMed 780G system (Medtronic) advanced hybrid closed-loop insulin delivery system aimed at simplifying the management of type 1 diabetes is now available in the UK for people aged 7 to 80 years.